Health Care Associated Infections in 2017
Acute Care Hospitals

Christina Brandeburg, MPH
Epidemiologist

Katherine T. Fillo, Ph.D, RN-BC
Director of Clinical Quality Improvement

Eileen McHale, RN, BSN
Healthcare Associated Infection Coordinator

Public Health Council
July 11, 2018
Introduction

Healthcare-associated infections (HAIs) are infections that patients acquire during the course of receiving treatment for other conditions within a healthcare setting.

HAIs are among the leading causes of preventable death in the United States, affecting 1 in 25 hospitalized patients, accounting for an estimated 722,000 infections and an associated 75,000 deaths during hospitalization.*

The Massachusetts Department of Public Health (DPH) developed this data update as a component of the Statewide Infection Prevention and Control Program created pursuant to Chapter 58 of the Acts of 2006.

- Massachusetts law provides DPH with the legal authority to conduct surveillance, and to investigate and control the spread of communicable and infectious diseases. ([MGL c. 111, sections 6 & 7](https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXVI/Chapter111/Section51H))

- DPH implements this responsibility in hospitals through the hospital licensing regulation. ([105 CMR 130.000](https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXVI/Chapter111/Section51H))

- Section 51H of chapter 111 of the Massachusetts General Laws authorizes the Department to collect HAI data and disseminate the information publicly to encourage quality improvement. ([https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXVI/Chapter111/Section51H](https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXVI/Chapter111/Section51H))

This HAI presentation is the ninth annual Public Health Council update:

• It is an important component of larger efforts to reduce preventable infections in health care settings;

• It presents an analysis of progress on infection prevention within Massachusetts acute care hospitals;

• It is based upon work supported by state funds and the Centers for Disease Control and Prevention (CDC); and

• It provides an overview of antibiotic resistance and stewardship activities.
Methods

This data summary includes the following statewide measures for the 2017 calendar year (January 1, 2017 – December 31, 2017) as reported to the CDC’s National Healthcare Safety Network (NHSN).

The DPH required measures are consistent with the Centers for Medicare and Medicaid Services quality reporting measures.

- Central line associated bloodstream infections (CLABSI) in intensive care units
- Catheter associated urinary tract infections (CAUTI) in intensive care units
- Specific surgical site infections (SSI); and
- Specific facility wide laboratory identified events (LabID).

*National baseline data for each measure are based on a statistical risk model derived from 2015 national data.
*All data were extracted from NHSN on June 11th, 2018.
• Standardized Infection Ratio (SIR)*

Standardized Infection Ratio (SIR) = \frac{\text{Actual Number of Infections}}{\text{Predicted Number of Infections}}

* When the actual number is equal to the predicted number the SIR = 1.0

• Central Line Utilization Ratio

Central Line Utilization Ratio = \frac{\text{Number of Central Line Days}}{\text{Number of Patient Days}}

• Urinary Catheter Utilization Ratio

Urinary Catheter Utilization Ratio = \frac{\text{Number of Urinary Catheter Days}}{\text{Number of Patient Days}}
SIR

The green horizontal bar represents the SIR, and the blue vertical bar represents the 95% confidence interval (CI). The 95% CI measures the probability that the true SIR falls between the two parameters.

- If the blue vertical bar crosses 1.0 (highlighted in orange), then the actual rate is not statistically significantly different from the predicted rate.
- If the blue vertical bar is completely above or below 1.0, then the actual is statistically significantly different from the predicted rate.
Massachusetts Central Line-Associated Bloodstream Infection (CLABSI) SIR, by ICU Type
January 1, 2017-December 31, 2017

Key Findings

Three ICU types experienced a significantly lower number of infections than predicted, based on 2015 national aggregate data:
  - Medical (T)
  - Medical /Surgical (T)
  - Surgical

One ICU type experienced a significantly higher number of infections than predicted, based on 2015 national aggregate data:
  - Burn

NT=Not major teaching
T= Major teaching
CLABSI Adult & Pediatric ICU
Pathogens for 2016 and 2017

Calendar Year 2016
January 1, 2016 – December 31, 2016
n=176

- Staphylococcus aureus (not MRSA): 8%
- Methicillin-resistant Staphylococcus: 2%
- Coagulase-negative Staphylococcus: 17%
- Enterococcus sp.: 16%
- Gram-positive bacteria (other): 6%
- Gram-negative bacteria: 17%
- Multiple Organisms: 11%
- Candida albicans: 10%
- Yeast/Fungus (other): 11%

Calendar Year 2017
January 1, 2017 – December 31, 2017
n=165

- Staphylococcus aureus (not MRSA): 7%
- Methicillin-resistant Staphylococcus: 5%
- Coagulase-negative Staphylococcus: 17%
- Enterococcus sp.: 16%
- Gram-positive bacteria (other): 6%
- Gram-negative bacteria: 17%
- Multiple Organisms: 11%
- Candida albicans: 12%
- Yeast/Fungus (other): 8%
- Coagulase-negative Staphylococcus: 16%
- Multiple Organisms: 10%
- Gram-negative bacteria: 24%
- Gram-positive bacteria (other): 9%
Massachusetts CLABSI SIR in NICUs, by Birth Weight Category
January 1, 2017-December 31, 2017

Key Findings

Infants weighing 1001 grams-1500 grams at birth experienced a significantly higher number of infections than predicted, based on 2015 national aggregate data.

There were 20 CLABSIs reported in this ICU type.
CLABSI NICU Pathogens for 2016 and 2017

Calendar Year 2016
January 1, 2016 – December 31, 2016
n=28

- Staphylococcus aureus (not MRSA): 39%
- Coagulase-negative Staphylococcus: 14%
- Escherichia coli: 18%
- Methicillin-resistant Staphylococcus aureus (MRSA): 4%
- Gram-negative bacteria (other): 18%
- Multiple Organisms: 7%
- Gram-negative bacteria (other): 18%

Calendar Year 2017
January 1, 2017 – December 31, 2017
n=20

- Staphylococcus aureus (not MRSA): 40%
- Coagulase-negative Staphylococcus: 25%
- Escherichia coli: 5%
- Enterococcus sp.: 5%
- Methicillin-resistant Staphylococcus aureus (MRSA): 4%
- Gram-negative bacteria (other): 10%
- Multiple Organisms: 10%
- Candida and other Yeast/Fungus: 5%
Key Findings

For the past three years, adult ICUs experienced a significantly lower number of infections than predicted, based on 2015 national aggregate data.

Over the past three years, neonatal ICUs have seen a decrease in the number of infections.
Key Findings

Discontinuing unnecessary central lines can reduce the risk for infection.

Central line (CL) utilization has remained relatively unchanged between 2015 and 2017.

*The CL utilization ratio is calculated by dividing the number of CL days by the number of patient days.*
Massachusetts Catheter-Associated Urinary Tract infection (CAUTI) SIR, by ICU Type
January 1, 2017-December 31, 2017

Key Findings

Two ICU types experienced a significantly lower number of infections than predicted, based on 2015 national aggregate data:
- Medical /Surgical (T)
- Trauma

One ICU type experienced a significantly higher number of infections than predicted, based on 2015 national aggregate data:
- Neurosurgical

NT=Not major teaching
T= Major teaching
**Calendar Year 2016**
January 1, 2016 – December 31, 2016

- **Escherichia coli**: 35%
- **Pseudomonas aeruginosa**: 13%
- **Klebsiella pneumoniae**: 12%
- **Coagulase-negative Staphylococcus**: 8%
- **Enterococcus sp.**: 6%
- **Multiple Organisms**: 2%
- **Gram-negative bacteria (other)**: 6%
- **Gram-positive bacteria (other)**: 8%
- **Staphylococcus aureus (not MRSA)**: 2%

**Calendar Year 2017**
January 1, 2017 – December 31, 2017

- **Escherichia coli**: 34%
- **Pseudomonas aeruginosa**: 13%
- **Klebsiella pneumoniae**: 12%
- **Coagulase-negative Staphylococcus**: 10%
- **Enterococcus sp.**: 10%
- **Multiple Organisms**: 8%
- **Gram-negative bacteria (other)**: 8%
- **Gram-positive bacteria (other)**: 13%
- **Staphylococcus aureus (not MRSA)**: 2%
Key Findings

Over the past three years, pediatric ICUs have seen an increase in the number of infections but are no different than predicted, based on 2015 national aggregate data.

There were 13 CAUTIs reported by 10 pediatric ICUs.
Key Findings

Discontinuing unnecessary urinary catheters can reduce the risk for infection.

Urinary catheter utilization in adult and pediatric ICUs has remained relatively unchanged between 2015 and 2017.

*The urinary catheter utilization ratio is calculated by dividing the number of catheter days by the number of patient days.
Key Findings

For the past three years, MA acute care hospitals performing coronary artery bypass graft procedures (CABG) and colon procedures (COLO) experienced the same number of infections as predicted, based on 2015 national aggregate data.

There were 33 CABG SSIs reported in 2017.

There were 173 COLO SSIs reported in 2017.
Key Findings

In 2017, Massachusetts acute care hospitals performing knee prosthesis procedures (KPRO) and hip prosthesis procedures (HPRO) experienced the same number of infections as predicted, based on 2015 national aggregate data.

There were 69 KPRO SSIs and 76 HPRO SSIs reported in 2017.
Key Findings

In 2017, Massachusetts acute care hospitals performing abdominal hysterectomy (HYST) and vaginal hysterectomy (VHYS) procedures experienced the same number of infections as predicted, based on 2015 national aggregate data.

There were 47 HYST SSIs and 10 VHYS SSIs reported in 2017.
Calendar Year 2016
January 1, 2016 – December 31, 2016
n=409

- Staphylococcus aureus (not MRSA): 14%
- Methicillin-resistant Staphylococcus aureus (MRSA): 8%
- Coagulase-negative Staphylococcus: 4%
- Gram-positive bacteria (other): 11%
- Gram-negative bacteria: 15%
- Multiple Organisms: 28%
- No Organism Identified: 17%
- Other: 3%

Calendar Year 2017
January 1, 2017 – December 31, 2017
n=408

- Staphylococcus aureus (not MRSA): 11%
- Methicillin-resistant Staphylococcus aureus (MRSA): 5%
- Coagulase-negative Staphylococcus: 6%
- Gram-positive bacteria (other): 11%
- Gram-negative bacteria: 20%
- Multiple Organisms: 29%
- Other: 1%
- No Organism Identified: 17%
Statistically Higher than Predicted

Statistically the Same as Predicted

Statistically Lower than Predicted


CABG  KPRO  HPRO  HYST  VHYS  COLO
Summary of SSI Results

- **Significantly Higher than Predicted**
  The number of infections reported is higher than the number of predicted infections.

- **Significantly Lower than Predicted**
  The number of infections reported is lower than the number of predicted infections.

- **Same as Predicted**
  The number of infections reported is the same as the number of predicted infections.
Key Findings

For the past two years, Massachusetts hospitals reporting CDI events experienced significantly lower number of infections than predicted, based on 2015 national aggregate data.

There were 2,186 CDI events reported in 2017.
Key Findings

For the past three years, Massachusetts acute care hospitals reporting MRSA events experienced significantly lower number of infections than predicted, based on 2015 national aggregate data.

There were 150 MRSA events reported in 2017.
Statewide LabID Trends by Year
2015-2017

CDI

MRSA

Statistically Higher than Predicted
Statistically the Same as Predicted
Statistically Lower than Predicted
Summary of LabID Results

Significantly Higher than Predicted
The number of infections reported is higher than the number of predicted infections.

Same as Predicted
The number of infections reported is the same as the number of predicted infections.

Significantly Lower than Predicted
The number of infections reported is lower than the number of predicted infections.
HAI Prevention Activities

• External data validation of *Clostridium difficile* infections conducted at 20 acute care hospitals and 10 long-term care facilities in the fall of 2017 and spring of 2018. DPH plans to conduct data validation of specific NHSN measures to ensure completeness and accuracy of reported data.

• Continued enrollment of long-term care facilities into NHSN for *Clostridium difficile* infection reporting.

• Ongoing data sharing with the Neonatal Quality Improvement Collaborative (NeoQIC) to address opportunities for improvement.

• Five hemodialysis infection prevention simulation trainings were held for hemodialysis nurses and technicians.

• On-site Infection Control Assessment and Response (ICAR) visits expanding from nursing homes to long-term acute care facilities.

• DPH monitors progress by providing quarterly Data Cleaning Reports and Targeted Assessment for Prevention (TAP) Reports for all hospitals to identify areas where focused infection prevention efforts are needed.

• Outreach to hospitals with higher than expected SIRs to ensure the need for improvement has been addressed.
• Antibiotic or antimicrobial resistance occurs when organisms are able to resist the effects of drugs. Bacteria are not killed by the antibiotic and continue to grow.

• Some individuals may be at a greater risk for acquiring a drug resistant infection (individuals with co-morbidities, previous hospitalizations, antibiotic exposures, etc.). However, drug-resistant infections can affect anyone.

• Infections with resistant organisms can be difficult to treat, are expensive and can have adverse effects.

• Inevitably, bacteria are able to adapt to newly developed antibiotics and become resistant.

• It is imperative to respond aggressively to prevent resistance and prevent the spread of existing resistant bacteria.
<table>
<thead>
<tr>
<th>MDRO Type</th>
<th>2016</th>
<th>2017</th>
<th>2018*</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Enterobacter cloacae</em></td>
<td>22</td>
<td>88</td>
<td>71</td>
<td>181</td>
</tr>
<tr>
<td><em>Klebsiella oxytoca and pneumoniae</em></td>
<td>15</td>
<td>78</td>
<td>33</td>
<td>126</td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>5</td>
<td>32</td>
<td>40</td>
<td>77</td>
</tr>
<tr>
<td><em>Enterobacter aerogenes</em></td>
<td>8</td>
<td>17</td>
<td>5</td>
<td>30</td>
</tr>
<tr>
<td><em>Candida auris</em></td>
<td>0</td>
<td>7</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>50</td>
<td>222</td>
<td>150</td>
<td>422</td>
</tr>
</tbody>
</table>

*Data are current as of June 30, 2018 and are subject to change.*
DPH provides epidemiologic investigation support and guidance when specific MDROs are suspected to mitigate any exposure.

Activities include:
- Provide detailed infection control recommendations;
- Recommend retrospective and prospective laboratory surveillance;
- Coordinates colonization screening of close contacts in collaboration with regional laboratory.

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Contact</td>
<td>75</td>
<td>10</td>
</tr>
<tr>
<td>Suspect</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

* Data are current as of June 30, 2018 and are subject to change.
• Studies indicate that between 30-50% of antibiotics prescribed in hospitals and between 40-75% of antibiotics prescribed in nursing homes is unnecessary*.

• Improved prescribing practices can help reduce rates of *Clostridium difficile* and antibiotic resistance.

• Appropriate antibiotic prescribing can improve patient outcomes and reduce healthcare costs.

*https://www.cdc.gov/antibiotic-use/healthcare/
https://www.cdc.gov/longtermcare/prevention/antibiotic-stewardship.html
• Electronic laboratory reporting (ELR) of mandatory MDROs of concern into the Massachusetts Virtual Epidemiologic Network (MAVEN).

• Mandatory submission of MDRO isolates to the Massachusetts State Public Health Laboratory for advanced testing;
  – Identify novel resistance mechanisms;
  – Identify *Candida auris*. 
• **NEW** - Nine part webinar series for long-term care and long-term acute care facilities, “Navigating Infection Control and Antibiotic Stewardship in Long-term Care” with three “ask the experts” calls.
• **NEW** - Collection, monitoring and reporting of facility-level antibiotic use data in long-term care facilities (n=45).
• **NEW** - “Bug of the Month” webinar series targeting MDROs of concern for all facility types.
• Publication of annual statewide antibiogram.
  – Provides bug-drug combinations of interest for benchmarking purposes ([https://www.mass.gov/service-details/massachusetts-antibiograms](https://www.mass.gov/service-details/massachusetts-antibiograms))
• Engagement with subject matter experts and stakeholders during quarterly statewide HAI/AR Technical Advisory Group (TAG) meetings.
Antibiotic Resistance and Antibiotic Stewardship: Antibiograms

Staphylococcus aureus Susceptibility Rates – 2017

Statewide

% Susceptibility

Antibiotic

Azithromycin
Ciprofloxacin
Clindamycin
Daptomycin
Erythromycin
Oxacillin
Quin/Dal
Tetracycline
TMS
Antibiotic Resistance and Antibiotic Stewardship: Next Steps

• Awarded competitive funding from the Council of State and Territorial Epidemiologists (CSTE) to modify the infection control assessment and response (ICAR) tool for use in long-term acute care hospitals (LTACHs) and to conduct enhanced education for managing and containing MDROs.

• Plan to collect and analyze NHSN antibiotic use (AU) data from a sample of acute care facilities to better understand trends in antibiotic use and monitor stewardship activities.

• Support and collaborate with two national Leadership in Epidemiology, Antimicrobial Stewardship and Public Health (LEAP) fellows, selected to improve the utility of the statewide antibiogram data and to enhance AS activities in long-term care facilities.

• Engage additional infection preventionists in use of MAVEN system for ease in response and containment of MDROs.
Thank you for the opportunity to present this information today.

Please direct any questions to:
Eileen McHale, RN, BSN
Healthcare Associated Infection Coordinator
Bureau of Health Care Safety and Quality
Eileen.mchale@state.ma.us